BioSpace News Archive

MedExecWomen is hosting the second MedExecWomen Annual Conference for women in the life sciences industry later this month in Boston. This year’s conference will be in person on Oct. 26, 2021, at the Sheraton Boston in Back Bay

PhaseBio Pharmaceuticals, Inc. today announced that REVERSE-IT has been accepted for presentation in a virtual Late Breaking Science session at the American Heart Association (AHA) Scientific Sessions 2021 on Monday, November 15, 2021.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, will participate at the H.C. Wainwright 5th Annual NASH Investor Conference.

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.

Legacy Healthcare, a clinical-stage biopharmaceutical company focused on developing novel drugs for autoimmune and inflammatory diseases, today announced that it has completed the enrollment of a Phase 2/3 trial of Coacillium (LH-8), an investigational drug for the treatment of moderate to severe scalp alopecia areata (i.e., baldness of 25% and above) in pediatric population.

Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced the dosing of the first patient in a first-in-human, dose escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held virtually October 6–7.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the peer-reviewed journal International Ophthalmology Clinics has published a review of current and past gene therapy clinical trials for the treatment of Leber hereditary optic neuropathy.

San Diego, USA, October 6th, 2021 – Covicept Therapeutics, an antiviral drug development company, announced that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19.